{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-22-000752","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2022-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.227630+00:00","generated_at":"2026-06-25T22:33:39.293191+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Arcturus Q1 net loss $51.2M ($1.94/share); ARCT-154 booster shows 54-fold Omicron BA.1 response","bullets":["Q1 2022 revenue $5.2M (up from $2.1M YoY); operating expenses $55.6M; net loss $51.2M.","Cash $319.7M at March 31, 2022; expected to fund operations into late 2023.","ARCT-154 booster data: 54-fold and 46-fold GMFR against Omicron BA.1 and BA.2 at Day 29.","Primary vaccine efficacy 95.3% against severe COVID-19; 55% overall; 98.4% seroconversion.","ARCT-810 Phase 2 OTC deficiency trial to start Q2 2022; ARCT-032 cystic fibrosis CTA filing on track for Q3 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-22-000752","json":"https://secwatch.observer/filing/0001193805-22-000752.json","markdown":"https://secwatch.observer/filing/0001193805-22-000752.md","text":"https://secwatch.observer/filing/0001193805-22-000752.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380522000752/0001193805-22-000752-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380522000752/e621634_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T22:33:39.293191+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}